Array BioPharma
| Company type | Subsidiary of Pfizer |
|---|---|
| Industry | Oncology Medication |
| Founded | 1998 |
| Founder | Dr. Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou |
| Headquarters | , |
| Parent | Pfizer |
| Website | www |
Array BioPharma is a U.S.-based, clinical stage, pharmaceutical company. The company is a subsidiary of Pfizer.
The company focuses on oncology medication.
History
In 1998, the company was founded by Dr. Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.
In November 2000, the company became a public company via an initial public offering.[1]
In July 2013, the company partnered with Loxo Oncology to develop cancer drugs.[2]
In November 2015, the company signed a partnership with Laboratoires Pierre Fabre.[3]
The company partnered with Ono Pharmaceutical in March 2016 to test the combination of binimetinib and encorafenib while retaining commercialization rights in the U.S. and other markets.[4][5]
In 2016, the company collaborated with Laboratoires Pierre Fabre for a phase three trial for a treatment of BRAF-mutant metastatic colorectal cancer.[6]
In 2017, the company spun out one of its programs into a subsidiary called Yarra; the asset was a molecule called ARRY-797 that was in a Phase II trial for cardiomyopathy.[7]
In March 2018, Array sued AstraZeneca for breach of contract, saying that AstraZeneca owed it a 12% royalty on a portion of the $1.6 billion upfront payment that Merck had paid to AstraZeneca in a deal for selumetinib, which Array said it had licensed to AstraZeneca in 2003.[8]
In June 2018, the combination of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) was approved by the Food and Drug Administration for the treatment of people with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma.[9]
On September 20, 2018, the European Commission approved BRAFTOVI® in combination with MEKTOVI® for the treatment of adult patients with unresectable or metastatic melanoma with a BRAFV600 mutation, as detected by a validated test. This approval is applicable to all 28 European Union member states, as well as Liechtenstein, Iceland, and Norway.[10]
In July 2019, Pfizer acquired the company.[11]
References
- ^ "Array IPO up 17%". CNN. November 17, 2000.
- ^ "Loxo Oncology And Array BioPharma Announce License And Collaboration Agreement" (Press release). PR Newswire. July 10, 2013.
- ^ "Innovation and Partnerships". Laboratoires Pierre Fabre.
- ^ Taylor, Phil (May 31, 2017). "Array adds Ono as Japanese partner for MEK/BRAF combo". Fierce Biotech.
- ^ Vinluan, Frank (June 1, 2017). "Array Lands $31M in Licensing Deal with Japan's Ono Pharma". Xconomy.
- ^ Hughes, Emily (June 6, 2016). "Merck, Pierre Fabre and Array BioPharma collaborate for cancer drug clinical trial". EPM Magazine.
- ^ Castle, Shay (December 26, 2017). "Boulder's Array BioPharma spins out subsidiary to develop rare-disease drugs". The Denver Post.
- ^ Vogt, RJ (March 19, 2018). "AstraZeneca Owes $192M For Cancer Drug Rights, Rival Says". Law360.
- ^ "Press release: FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations" (Press release). Food and Drug Administration. June 27, 2018.
- ^ "Pierre Fabre Receives EU Approval for BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) in Adult Patients with Advanced BRAF-Mutant Melanoma" (Press release). Business Wire. September 20, 2018.
- ^ "PFIZER COMPLETES ACQUISITION OF ARRAY BIOPHARMA" (Press release). Pfizer. July 30, 2019.